For a long time, the upgrading of pet nutrition products has largely focused on ingredient levels: higher concentrations, more diverse strain combinations, and the addition of an increasing number of functional ingredients. While this strategy has driven industry development to a certain extent, it has also gradually revealed the issue of inconsistent effectiveness in actual feeding practices.

For the same probiotics or functional ingredients, some pets show obvious responses, while others exhibit only limited effects—or even fail to show any noticeable change after consumption.

From a formulation and physiological perspective, this difference does not entirely stem from individual variations but rather from the active ingredient. Stability during the digestion process Closely related.

The digestive systems of pets differ significantly from those of humans. Taking dogs and cats as examples, compared to humans, Its gastric acid environment is more intense, its eating rhythm is concentrated, and its digestive process is short and rapid. If the active ingredient is already largely inactivated before it reaches the intestine, the theoretical advantages of the formulation will be difficult to translate into actual efficacy.

Based on this reality, NEWGEN is shifting its focus from merely optimizing individual ingredients to studying the digestion process itself. By adjusting the formulation structure, the active ingredients can be more stably protected and released at a controlled pace during digestion, thereby better meeting the real needs of pets over the long term.

Reunderstanding the pet CrystoGen ^TM The value of microcrystal sphere technology

CrystoGen ^TM The core of microcrystal sphere technology isn't simply "encapsulating the ingredients"; rather, it involves structural design to ensure that active ingredients receive more appropriate protection and release timing during digestion—allowing them to “complete this journey” more stably.

CrystoGen ^TM Adopt a multi-layered structure, with each layer performing its own specific function:

The outer layer is designed to mitigate the effects of early digestive environments, such as gastric acid and bile.
The intermediate layer regulates the release rate, preventing premature or concentrated release of the active ingredient.
The core layer enables the active ingredients to be gradually released in a relatively favorable intestinal environment, ensuring that these active ingredients participate more stably in the digestion and absorption processes.

For pets, the value of this design lies in its stability. Rather than seeking a strong, short-term response, it ensures that nutritional supplementation becomes more predictable, gentler, and better aligned with the pet’s own physiological rhythms over the long term.

Building on this foundation, CrystoGen™ also takes into account the stability requirements at the practical application level. Through low-temperature encapsulation and structural optimization, the active ingredient not only maintains high activity but also exhibits excellent storage stability and formulation compatibility, making it suitable for a wide range of application scenarios and various product dosage forms.
 

From ingredient stacking to scientific release, the microcrystalline spheres of CrystoGen™ represent not merely an upgrade in formulation technology, but a fundamental rethinking of the nutritional logic underlying pet gut health. Only when active ingredients can reliably “make it all the way” can the true value of nutritional supplementation transcend the formulation table and truly come alive in real-world feeding scenarios.

—About NEWGEN— About Us

Ningbo Xinoa Marine Biotechnology Co., Ltd. is located in Xiangshan County, Ningbo City. Founded in 2013, the company was established by Zhu Hui, an immunology expert who returned to China from the United States. It is a high-tech enterprise that leverages marine biological resources and employs synthetic biology technologies to develop natural, bioactive macromolecular products derived from marine organisms. The company aims to provide innovative solutions for intestinal nutrition and health, thereby boosting the development of nutritional and health services.

The company is at a globally advanced level in the fields of marine polysaccharides, marine enzyme preparations, and intestinal microbiota. Leveraging its strong capabilities and cutting-edge technologies in the marine biopharmaceutical sector, the company has undertaken numerous national, provincial, and municipal R&D projects, including the National “13th Five-Year Plan” Marine Innovation Development and Demonstration Project, Ningbo’s “2025 Science and Technology Breakthrough” Major Special Project, and Ningbo’s “Challenge-Based Recruitment and Leadership” Major Special Project.

The company has obtained numerous quality system certifications, including ISO 22000:2015 Food Management System, ISO 9001:2015 Management System, HACCP Food Management System, Kosher, Halal, and NSF-CGMP. It is a member of several international associations, such as the IPA (International Probiotics Association) and the ETA (Enzyme Technical Association). The company has also received multiple provincial- and city-level awards for technological innovation, including the Third Prize of the China Commercial Federation Science and Technology Award, the Second Prize of the China Invention Association, and the Third Prize of the Ningbo City Science and Technology Progress Award. The company places great emphasis on intellectual property protection; as of 2023, it has filed over 70 patent applications and been granted 36 patents, including 23 authorized invention patents.